Spinal cord neuroblastoma

Summary

Spinal cord neuroblastoma (MONDO:0004024) is a disease. A subtype of central nervous system primitive neuroectodermal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord neuroblastoma
Mondo ID	MONDO:0004024
DOID	DOID:6871
NCIT	C5155
UMLS	C1336046
MedGen	234803
GARD	0023783
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	no

Also known as: neuroblastoma of spinal cord · spinal cord neuroblastoma

Disease family

This is a subtype of central nervous system primitive neuroectodermal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system primitive neuroectodermal neoplasm › spinal cord neuroblastoma

Related subtypes (7): adult central nervous system primitive neuroectodermal neoplasm, childhood central nervous system primitive neuroectodermal neoplasm, intracranial primitive neuroectodermal tumor, ganglioneuroma, spinal cord primitive neuroectodermal tumor, ependymoblastoma, central nervous system tumor with bcor internal tandem duplication

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.